期刊
ONCOTARGET
卷 8, 期 33, 页码 55715-55730出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.18382
关键词
hepatocellular carcinoma; driver mutations; driver identification; targeted therapy; precision medicine
资金
- National Natural Science Foundation of China [61372151]
- National Science Foundation for Young Scientists of China [81602483]
- Fundamental Research Funds for the Central Universities [xjj2017121]
- China Postdoctoral Science Foundation [2016M602798]
Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumulated diverse genetic mutations, which confer selective growth advantages to tumor cells and are called driver mutations. The discovery of driver mutations provides a novel precision medicine strategy for late stage HCC, called targeted therapy. In this review, we summarized currently discovered driver mutations and corresponding signaling pathways, made an overview of identification methods of driver mutations and genes, and classified targeted drugs for HCC. The knowledge of mutational landscape deepen our understanding of carcinogenesis and promise future precision medicine for HCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据